ALK rearrangements were initially identified in large-cell lymphomas, but the discovery of the EML4-ALK fusion in NSCLC in 2007 established ALK as a key oncogenic driver in this disease [92,93]. This evidence concerns the gene ALK and non-small cell lung carcinoma.